Avalo Therapeutics Valuation
Is AVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AVTX?
Other financial metrics that can be useful for relative valuation.
| What is AVTX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$46.13m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.9x |
| Enterprise Value/EBITDA | -1.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AVTX's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.1x | ||
ABEO Abeona Therapeutics | 10.1x | 55.2% | US$44.0m |
MEIP MEI Pharma | 1.1x | 45.7% | US$45.3m |
DYAI Dyadic International | 17.7x | 30.6% | US$44.3m |
BCDA BioCardia | 35.6x | 66.7% | US$47.1m |
AVTX Avalo Therapeutics | 2.7x | 41.3% | US$46.1m |
Price-To-Sales vs Peers: AVTX is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (16.1x).
Price to Earnings Ratio vs Industry
How does AVTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is AVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.7x |
| Fair PS Ratio | 1.5x |
Price-To-Sales vs Fair Ratio: AVTX is expensive based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).
Share Price vs Fair Value
What is the Fair Price of AVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AVTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AVTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$4.90 | US$10.63 +116.8% | 38.7% | US$17.00 | US$5.50 | n/a | 4 |
| Jan ’24 | US$5.04 | US$10.63 +110.8% | 38.7% | US$17.00 | US$5.50 | n/a | 4 |
| Dec ’23 | US$5.69 | US$10.63 +86.7% | 38.7% | US$17.00 | US$5.50 | n/a | 4 |
| Nov ’23 | US$6.65 | US$11.38 +71.1% | 50.1% | US$17.00 | US$4.50 | n/a | 4 |
| Oct ’23 | US$3.32 | US$11.38 +242.6% | 50.1% | US$17.00 | US$4.50 | n/a | 4 |
| Sep ’23 | US$4.70 | US$11.38 +142.0% | 50.1% | US$17.00 | US$4.50 | n/a | 4 |
| Aug ’23 | US$3.60 | US$43.50 +1,108.3% | 69.1% | US$84.00 | US$9.00 | n/a | 4 |
| Jul ’23 | US$6.24 | US$42.60 +582.7% | 62.4% | US$84.00 | US$9.00 | n/a | 5 |
| Jun ’23 | US$3.84 | US$42.60 +1,009.0% | 62.4% | US$84.00 | US$9.00 | n/a | 5 |
| May ’23 | US$4.93 | US$47.40 +861.5% | 52.6% | US$84.00 | US$9.00 | n/a | 5 |
| Apr ’23 | US$10.45 | US$47.40 +353.4% | 52.6% | US$84.00 | US$9.00 | n/a | 5 |
| Mar ’23 | US$9.82 | US$60.00 +510.9% | 25.3% | US$84.00 | US$36.00 | n/a | 5 |
| Feb ’23 | US$12.00 | US$69.00 +475.0% | 14.4% | US$84.00 | US$60.00 | n/a | 4 |
| Jan ’23 | US$20.40 | US$72.00 +252.9% | 14.9% | US$84.00 | US$60.00 | US$5.04 | 5 |
| Dec ’22 | US$22.44 | US$72.00 +220.9% | 14.9% | US$84.00 | US$60.00 | US$5.69 | 5 |
| Nov ’22 | US$28.68 | US$76.80 +167.8% | 12.5% | US$84.00 | US$60.00 | US$6.65 | 5 |
| Oct ’22 | US$27.00 | US$76.80 +184.4% | 12.5% | US$84.00 | US$60.00 | US$3.32 | 5 |
| Sep ’22 | US$38.88 | US$78.00 +100.6% | 13.3% | US$84.00 | US$60.00 | US$4.70 | 4 |
| Aug ’22 | US$31.92 | US$84.00 +163.2% | 18.1% | US$108.00 | US$60.00 | US$3.60 | 5 |
| Jul ’22 | US$40.68 | US$81.60 +100.6% | 23.5% | US$108.00 | US$48.00 | US$6.24 | 5 |
| Jun ’22 | US$33.36 | US$93.60 +180.6% | 33.8% | US$144.00 | US$48.00 | US$3.84 | 5 |
| May ’22 | US$37.68 | US$98.40 +161.1% | 32.2% | US$144.00 | US$48.00 | US$4.93 | 5 |
| Apr ’22 | US$36.60 | US$120.00 +227.9% | 14.1% | US$144.00 | US$108.00 | US$10.45 | 3 |
| Mar ’22 | US$44.76 | US$120.00 +168.1% | 14.1% | US$144.00 | US$108.00 | US$9.82 | 3 |
| Feb ’22 | US$37.80 | US$112.00 +196.3% | 22.0% | US$144.00 | US$84.00 | US$12.00 | 3 |
| Jan ’22 | US$31.68 | US$112.00 +253.5% | 22.0% | US$144.00 | US$84.00 | US$20.40 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
- Take a look at our analysis of AVTX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Potentially undervalued companies in the Pharmaceuticals & Biotech industry.